

NOTICE OF ALLOWANCE

This action is in response to the amendment filed October 9, 2009. Applicant has cancelled Claims 1-6, 8 and 11-68, and amended Claim 9, and added new claims, Claims 73-76. All of the amendments have been thoroughly reviewed and entered.

Examiner's Amendment

1. **An Examiner's amendment to the record appears below.** Should the changes and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this Examiner's amendment was given in a telephone interview with Applicant's representative, Forrester Little at 617-897-2035, on November 20, 2009.

The claims have been amended as follows:

1. Claims 7, 9-10 and 69-71 have been cancelled.
2. In claim 72, line 3, the phrase "a fatty acid" was replaced with the phrase "a functionally active fatty acid".
3. In claim 74, line 1, the phrase "the FADS2" was replaced with the phrase "the functionally active FADS2".
4. In claim 75, line 1, the phrase "the FADS2" was replaced with the phrase "the functionally active FADS2".
5. In claim 76, line 1, the phrase "the FADS2" was replaced with the phrase "the functionally active FADS2".

Allowable Subject Matter

2. **Claims 72-76 are allowed. The following is a statement of reasons for the indication of allowable subject matter:** The prior art does not teach or reasonably suggest a sufficient

Art Unit: 1633

nexus that FADS2 plays a functional role in the processing of APP by gamma secretase. The specification supports the use of test compounds that decrease FADS2 activity which consequently inhibits gamma secretase activity to achieve the reduced production of Abeta-42.

Any comments considered necessary by Applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

3. Claims 72-76 are allowed.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to KEVIN K. HILL whose telephone number is (571)272-8036. The Examiner can normally be reached on Monday through Friday, between 9:00am-6:00pm EST.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Joseph T. Woitach can be reached on 571-272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Kevin K. Hill/

Examiner, Art Unit 1633